Business Context and Reporting Period
Company: Compugen Ltd. (CGEN)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Compugen is a clinical-stage therapeutic discovery and development company utilizing its AI/ML-powered predictive computational discovery platform, Unigen™, to identify novel drug targets and develop therapeutics in cancer immunotherapy. The company has no approved products and relies on collaborations for revenue.
Key Financial Metrics
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $27.9 million | $33.5 million | $7.5 million |
| Net Loss | $(14.2) million | $(18.8) million | $(33.7) million |
| Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.21) | $(0.39) |
| Research & Development Expenses | $24.8 million | $34.5 million | $30.6 million |
| Operating Cash Flow | $49.6 million (Provided) | $(35.9) million (Used) | $(34.1) million (Used) |
| Cash, Cash Equivalents & Marketable Securities | $103.3 million | $50.7 million | N/A |
| Accumulated Deficit | $(488.8) million | $(474.5) million | $(455.8) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 17% to $27.9 million in 2024 compared to $33.5 million in 2023. This was primarily due to the timing of revenue recognition from the Gilead license agreement (upfront and milestone payments allocated to performance obligations) and a $5 million milestone from AstraZeneca, compared to higher recognition in 2023.
- Improved Net Loss: Net loss narrowed by 24% to $14.2 million, driven by a 28% reduction in R&D expenses and increased financial income ($5.2 million vs. $3.2 million in 2023) due to higher interest rates on cash balances.
- Cost of Revenues Increase: Cost of revenues rose to $7.9 million from $2.0 million, reflecting the classification of GS-0321 (COM503) development costs to cost of revenues and royalty payments, partially offset by a royalty reversal related to IIA exemptions.
- Liquidity Improvement: Cash and cash equivalents increased significantly to $103.3 million, bolstered by $91.5 million in net payments received from Gilead and AstraZeneca and proceeds from share sales.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management believes current cash resources are sufficient to fund operations into 2027 based on current plans, excluding potential additional funding from collaborations or financings.
- Clinical Milestones:
- COM701: Plans to start enrollment in a new adaptive platform trial for relapsed platinum-sensitive ovarian cancer in Q2 2025, with interim data expected in H2 2026.
- GS-0321 (COM503): First patient dosed in Phase 1 trial on January 7, 2025.
- Rilvegostomig (AstraZeneca): In multiple Phase 3 trials; AstraZeneca provided a non-risk adjusted peak year revenue target of over $5 billion.
Key Risks and Contingencies
- Geopolitical Risk: Operations are headquartered in Israel. The "Swords of Iron" war and regional hostilities pose risks to operations, employee availability (reserve duty), and supply chains, though no material impact has been reported to date.
- Dependency on Partners: The company is highly dependent on the success of COM701, COM902, GS-0321, and rilvegostomig. Termination of agreements with Gilead or AstraZeneca would materially harm the business.
- Clinical Trial Risks: High risk of failure in clinical trials, including potential setbacks in the TIGIT inhibitor space (relevant to COM902 and rilvegostomig) following mixed results from competitors.
- Intellectual Property: Ongoing European patent oppositions regarding anti-PVRIG antibodies (COM701) and screening methods.
- Regulatory/Tax: Contingent royalty obligations to the Israel Innovation Authority (IIA) totaling approximately $9.9 million as of year-end.
Investor Verification Checklist
- Cash Burn Rate: Verify if the projected runway into 2027 holds given the increased clinical activity for COM701 and GS-0321.
- Revenue Recognition: Review the allocation of the Gilead transaction price between the license, IND services, and Phase 1 services to understand future revenue recognition patterns.
- Israel Geopolitics: Monitor the impact of the ongoing conflict on employee retention, reserve call-ups, and insurance costs.
- Competitive Landscape: Assess the impact of recent failures in TIGIT inhibitor trials (e.g., Roche, Merck) on the valuation and partnership potential of COM902 and rilvegostomig.
- Patent Status: Track the outcome of the European Patent Office oppositions regarding COM701 patents.